Association of tumor TROP2 expression with prognosis varies among lung cancer subtypes

Oncotarget

Volumn 8, Issue 17, 2017, Pages 28725-28735

  Inamura, Kentaro ^a   Yokouchi, Yusuke ^b   Kobayashi, Maki ^a   Ninomiya, Hironori ^a   Sakakibara, Rie ^a,c   Subat, Sophia ^a   Nagano, Hiroko ^a   Nomura, Kimie ^a   Okumura, Sakae ^d   Shibutani, Tomoko ^b   Ishikawa, Yuichi ^a  

^a CANCER INSTITUTE   (Japan)

^b DAIICHI SANKYO CO   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^d CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

Antibody drug conjugate; Lung cancer; Molecular targeted therapy; Outcome; TROP2

Indexed keywords

MEMBRANE PROTEIN; PROTEIN TROP2; UNCLASSIFIED DRUG; CELL ADHESION MOLECULE; TACSTD2 PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; ALK GENE; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; EGFR GENE; FEMALE; GENE; GENE FUSION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEUROENDOCRINE TUMOR; ONCOGENE K RAS; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SEX DIFFERENCE; SMOKING; SQUAMOUS CELL LUNG CARCINOMA; TUMOR DIFFERENTIATION; TUMOR VOLUME; ADENOCARCINOMA; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; MOLECULARLY TARGETED THERAPY; MORTALITY; PROGNOSIS; SQUAMOUS CELL CARCINOMA; SURVIVAL ANALYSIS; TUMOR CELL LINE; UPREGULATION;

ADENOCARCINOMA; ANTIGENS, NEOPLASM; BIOMARKERS, TUMOR; CARCINOMA, SQUAMOUS CELL; CELL ADHESION MOLECULES; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEUROENDOCRINE TUMORS; PROGNOSIS; SURVIVAL ANALYSIS; UP-REGULATION;

EID: 85018413261     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.15647     Document Type: Article

References (43)

1. Kobayashi H, Minami Y, Anami Y, Kondou Y, Iijima T, Kano J, Morishita Y, Tsuta K, Hayashi S, Noguchi M. Expression of the GA733 gene family and its relationship to prognosis in pulmonary adenocarcinoma. Virchows Arch. 2010; 457:69-76
2. Pak MG, Shin DH, Lee CH, Lee MK. Significance of EpCAM and TROP2 expression in non-small cell lung cancer. World J Surg Oncol. 2012; 10:53
3. Li Z, Jiang X, Zhang W. TROP2 overexpression promotes proliferation and invasion of lung adenocarcinoma cells. Biochem Biophys Res Commun. 2016; 470:197-204
4. Liu T, Liu Y, Bao X, Tian J, Liu Y, Yang X. Overexpression of TROP2 predicts poor prognosis of patients with cervical cancer and promotes the proliferation and invasion of cervical cancer cells by regulating ERK signaling pathway. PLoS One. 2013; 8:e75864
5. Cardillo TM, Govindan SV, Sharkey RM, Trisal P, Arrojo R, Liu D, Rossi EA, Chang CH, Goldenberg DM. Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers. Bioconjug Chem. 2015; 26:919-931
6. Trerotola M, Ganguly KK, Fazli L, Fedele C, Lu H, Dutta A, Liu Q, De Angelis T, Riddell LW, Riobo NA, Gleave ME, Zoubeidi A, Pestell RG, et al. Trop-2 is up-regulated in invasive prostate cancer and displaces FAK from focal contacts. Oncotarget. 2015; 6:14318-28. doi: 10.18632/oncotarget.3960
7. Mao Y, Wang X, Zheng F, Wang C, Tang Q, Tang X, Xu N, Zhang H, Zhang D, Xiong L, Liang J, Zhu J. The tumorinhibitory effectiveness of a novel anti-Trop2 Fab conjugate in pancreatic cancer. Oncotarget. 2016; 7:24810-23. doi: 10.18632/oncotarget.8529
8. Xie J, Mølck C, Paquet-Fifield S, Butler L, Sloan E, Ventura S, Hollande F, Australian Prostate Cancer Bioresource. High expression of TROP2 characterizes different cell subpopulations in androgen-sensitive and androgen-independent prostate cancer cells. Oncotarget. 2016; 7:44492-504. doi: 10.18632/oncotarget.9876
9. Xu N, Zhang Z, Zhu J, Xu L, Li Y, Duan L, Mao Y, Li H. Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma. Int J Exp Pathol. 2016; 97:150-158
10. Zhao W, Zhu H, Zhang S, Yong H, Wang W, Zhou Y, Wang B, Wen J, Qiu Z, Ding G, Feng Z, Zhu J. Trop2 is overexpressed in gastric cancer and predicts poor prognosis. Oncotarget. 2016; 7:6136-45. doi: 10.18632/oncotarget.6733
11. Shvartsur A, Bonavida B. Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications. Genes Cancer. 2015; 6:84-105. doi: 10.18632/genesandcancer.40
12. Liu S-H, Strop P, Tran T-T, Dorywalska M, Delaria K, Ho W-H, Dushin R, Pons J, Rajpal A, Shelton D. Abstract 2640: RN927C, a potent site-specific Trop-2 antibodydrug-conjugate (ADC) for treatment of solid tumors. Cancer Research. 2014; 74:2640
13. oldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget. 2015; 6:22496-512. doi: 10.18632/oncotarget.4318
14. Starodub A, Camidge DR, Ronald J. Scheff RJ, Thomas SS, Guarino MJ, Masters GA, Kalinsky K, Gandhi L, Bardia A, Messersmith WA, Ocean AJ, Maliakal PP, Sharkey RM, et al. Trop-2 as a therapeutic target for the antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132), in patients (pts) with previously treated metastatic small-cell lung cancer (mSCLC). J Clin Oncol. 2016; 34: abst 8559
15. Camidge DR, Heist RS, Masters GA, Scheff RJ, Starodub A, Messersmith WA, Bardia A, Ocean AJ, Horn L, Berlin J, Maliakal PP, Sharkey RM, Wilhelm F, et al. Therapy of metastatic, non-small cell lung cancer (mNSCLC) with the anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132). J Clin Oncol. 2016; 34: abst 9011
16. Sharkey RM, McBride WJ, Cardillo TM, Govindan SV, Wang Y, Rossi EA, Chang CH, Goldenberg DM. Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan). Clin Cancer Res. 2015; 21:5131-5138
17. Chang CH, Wang Y, Zalath M, Liu D, Cardillo TM, Goldenberg DM. Combining ABCG2 Inhibitors with IMMU-132, an Anti-Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers. Mol Cancer Ther. 2016; 15:1910-1919
18. Strop P, Tran TT, Dorywalska M, Delaria K, Dushin R, Wong OK, Ho WH, Zhou D, Wu A, Kraynov E, Aschenbrenner L, Han B, O'Donnell CJ, et al. RN927C, a site-specific Trop-2 antibody-drug-conjugate (ADC) with enhanced stability, is highly efficacious in preclinical solid tumor models. Mol Cancer Ther. 2016; 15:2698-2708
19. Bardia A, Diamond JR, Mayer IA, Starodub AN, Moroose RL, Isakoff SJ, Ocean AJ, Guarino MJ, Berlin JD, Messersmith WA, Thomas SS, O'Shaughnessy JA, Kalinsky K, et al. Safety and efficacy of anti-Trop-2 antibody drug conjugate, sacituzumab govitecan (IMMU-132), in heavily pretreated patients with TNBC. Cancer Research. 2016; 76: abst PD3-06
20. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, Nardone J, Lee K, Reeves C, Li Y, Hu Y, Tan Z, Stokes M, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007; 131:1190-1203
21. Govindan R, Ding L, Griffith M, Subramanian J, Dees ND, Kanchi KL, Maher CA, Fulton R, Fulton L, Wallis J, Chen K, Walker J, McDonald S, et al. Genomic landscape of nonsmall cell lung cancer in smokers and never-smokers. Cell. 2012; 150:1121-1134
22. Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, Cho J, Suh J, Capelletti M, Sivachenko A, Sougnez C, Auclair D, Lawrence MS, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 2012; 150:1107-1120
23. The Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012; 489:519-525
24. The Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014; 511:543-550
25. George J, Lim JS, Jang SJ, Cun Y, Ozretic L, Kong G, Leenders F, Lu X, Fernandez-Cuesta L, Bosco G, Muller C, Dahmen I, Jahchan NS, et al. Comprehensive genomic profiles of small cell lung cancer. Nature. 2015; 524:47-53
26. Huang P, Cheng CL, Chang YH, Liu CH, Hsu YC, Chen JS, Chang GC, Ho BC, Su KY, Chen HY, Yu SL. Molecular gene signature and prognosis of non-small cell lung cancer. Oncotarget. 2016; 7:51898-907. doi: 10.18632/oncotarget.10622
27. Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S, Asaka R, Hamanaka W, Ninomiya H, Uehara H, Lim Choi Y, Satoh Y, Okumura S, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012; 18:378-381
28. Inamura K, Ishikawa Y. MicroRNA In Lung Cancer: Novel Biomarkers and Potential Tools for Treatment. J Clin Med. 2016; 5:36
29. Tang Y, Fang W, Zhang Y, Hong S, Kang S, Yan Y, Chen N, Zhan J, He X, Qin T, Li G, Tang W, Peng P, Zhang L. The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs. Oncotarget. 2015; 6:14209-19. doi: 10.18632/oncotarget.3694
30. Mao Y, Li W, Chen K, Xie Y, Liu Q, Yao M, Duan W, Zhou X, Liang R, Tao M. B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer. Oncotarget. 2015; 6:3452-61. doi: 10.18632/oncotarget.3097
31. Inamura K, Yokouchi Y, Sakakibara R, Kobayashi M, Subat S, Ninomiya H, Nagano H, Nomura K, Okumura S, Ishikawa Y. Relationship of tumor PD-L1 expression with EGFR wild-type status and poor prognosis in lung adenocarcinoma. Jpn J Clin Oncol. 2016; 46:935-941
32. Ishii H, Azuma K, Kawahara A, Yamada K, Imamura Y, Tokito T, Kinoshita T, Kage M, Hoshino T. Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer. J Thorac Oncol. 2015; 10:426-430
33. Miao L, Lu Y, Xu Y, Zhang G, Huang Z, Gong L, Fan Y. PD-L1 and c-MET expression and survival in patients with small cell lung cancer. Oncotarget. 2016 June 1. doi: 10.18632/oncotarget.9765 [Epub Ahead of Print]
34. Rekhtman N, Pietanza MC, Hellmann MD, Naidoo J, Arora A, Won H, Halpenny DF, Wang H, Tian SK, Litvak AM, Paik PK, Drilon AE, Socci N, et al. Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinomalike Subsets. Clin Cancer Res. 2016; 22:3618-3629
35. Ito T, Matsubara D, Tanaka I, Makiya K, Tanei ZI, Kumagai Y, Shiu SJ, Nakaoka HJ, Ishikawa S, Isagawa T, Morikawa T, Shinozaki-Ushiku A, Goto Y, et al. Loss of YAP1 defines neuroendocrine differentiation of lung tumors. Cancer Sci. 2016; 107:1527-1538
36. Stjernstrom A, Karlsson C, Fernandez OJ, Soderkvist P, Karlsson MG, Thunell LK. Alterations of INPP4B, PIK3CA and pAkt of the PI3K pathway are associated with squamous cell carcinoma of the lung. Cancer Med. 2014; 3:337-348
37. Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. (2015). WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart, 4th ed. (Lyon: IARC Press)
38. Japan Lung Cancer Society. (1999). General Rules for Clinical and Pathologic Record of Lung Cancer [in Japanese], 5th ed. (Tokyo: Kanahara)
39. Inamura K, Satoh Y, Okumura S, Nakagawa K, Tsuchiya E, Fukayama M, Ishikawa Y. Pulmonary adenocarcinomas with enteric differentiation: histologic and immunohistochemical characteristics compared with metastatic colorectal cancers and usual pulmonary adenocarcinomas. Am J Surg Pathol. 2005; 29:660-665
40. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. (2010). AJCC cancer staging manual. (New York: Springer)
41. Hiramatsu M, Ninomiya H, Inamura K, Nomura K, Takeuchi K, Satoh Y, Okumura S, Nakagawa K, Yamori T, Matsuura M, Morikawa T, Ishikawa Y. Activation status of receptor tyrosine kinase downstream pathways in primary lung adenocarcinoma with reference of KRAS and EGFR mutations. Lung Cancer. 2010; 70:94-102
42. Inamura K, Yokouchi Y, Kobayashi M, Sakakibara R, Ninomiya H, Subat S, Nagano H, Nomura K, Okumura S, Shibutani T, Ishikawa Y. Tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis. Lung Cancer. 2017; 103:44-51
43. Inamura K, Togashi Y, Nomura K, Ninomiya H, Hiramatsu M, Okui M, Satoh Y, Okumura S, Nakagawa K, Tsuchiya E, Ishikawa Y. Up-regulation of PTEN at the transcriptional level is an adverse prognostic factor in female lung adenocarcinomas. Lung Cancer. 2007; 57:201-206